Wells Fargo
CTKB icon

Wells Fargo’s Cytek Biosciences CTKB Stock Holding History

Wells Fargo’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$455K Buy
102,704
+57,427
+127% +$245K ﹤0.01% 4691
2026
Q1 		$198K Sell
45,277
-87,398
-66% -$413K ﹤0.01% 4708
2025
Q4 		$670K Buy
132,675
+42,274
+47% +$196K ﹤0.01% 4258
2025
Q3 		$314K Buy
90,401
+14,950
+20% +$56.1K ﹤0.01% 4653
2025
Q2 		$257K Buy
75,451
+3,963
+6% +$13.2K ﹤0.01% 4621
2025
Q1 		$287K Buy
71,488
+248
+0.3% +$1.28K ﹤0.01% 4458
2024
Q4 		$462K Buy
71,240
+15,516
+28% +$92.4K ﹤0.01% 4231
2024
Q3 		$309K Buy
55,724
+2,394
+4% +$13.6K ﹤0.01% 4296
2024
Q2 		$298K Buy
53,330
+17,189
+48% +$103K ﹤0.01% 4246
2024
Q1 		$243K Buy
36,141
+4,846
+15% +$38.3K ﹤0.01% 4352
2023
Q4 		$285K Buy
31,295
+7,021
+29% +$44.2K ﹤0.01% 4246
2023
Q3 		$134K Sell
24,274
-30,611
-56% -$246K ﹤0.01% 4602
2023
Q2 		$469K Buy
54,885
+32,800
+149% +$294K ﹤0.01% 3993
2023
Q1 		$203K Buy
22,085
+20,995
+1,926% +$226K ﹤0.01% 4419
2022
Q4 		$11.1K Sell
1,090
-763
-41% -$10.3K ﹤0.01% 5506
2022
Q3 		$27K Sell
1,853
-692
-27% -$8.99K ﹤0.01% 5244
2022
Q2 		$27K Sell
2,545
-35,806
-93% -$356K ﹤0.01% 5293
2022
Q1 		$413K Buy
38,351
+12,930
+51% +$175K ﹤0.01% 4546
2021
Q4 		$415K Buy
25,421
+25,340
+31,284% +$531K ﹤0.01% 4806
2021
Q3 		$2K Buy
+81
New +$1.91K ﹤0.01% 6559

Other funds holding CTKB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Wells Fargo's CTKB Position: Q2 2026 in Review

Wells Fargo increased its Cytek Biosciences (CTKB) stake by 127% in Q2 2026, buying an estimated $245K and bringing the position to 102,704 shares worth $455K. The position accounts for ﹤0.01% of the portfolio, ranked #4691.

Wells Fargo first reported a position in CTKB in Q3 2021 and has held it in 20 quarters since. The position peaked at $670K in Q4 2025. 154 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

  • Wells Fargo held 102,704 shares of Cytek Biosciences worth $455K as of Q2 2026.
  • Wells Fargo bought 57,427 Cytek Biosciences shares in Q2 2026, an estimated $245K.
  • Cytek Biosciences made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #4691 holding.
  • Wells Fargo first reported a position in Cytek Biosciences in Q3 2021 and has held it in 20 quarters since.
  • Wells Fargo's Cytek Biosciences position peaked at $670K in Q4 2025.
  • 154 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.